Bonus BioGroup
Press Room

Friday, 18 April 2014 07:38

Bonus BioGroup Announces Support by Chief Scientist of R&D Activities Including A Clinical Trial

Rate this item
(0 votes)

Bonus BioGroup Announces Support by Chief Scientist of R&D Activities Including A Clinical Trial

logo4footerBonus BioGroup announces that on May 18, 2014, the Office of the Israeli Chief Scientist approved R&D support for year 2014 in the amount of 2 million NIS for Bonus Therapeutics Ltd., a wholly-owned subsidiary of Bonus BioGroup. 

The R&D activities will include a clinical trial for the repair of human facial bone deficiencies, including upper or lower jawbone cavitation, by transplantation of live human bone grafts manufactured in the Company's production facility at MATAM Advanced Technology Park in Haifa.

On April 28, 2014, the first transplantation took place in the framework of the clinical trial. The Company estimates that interim results regarding the integration of the grafts will become available approximately 4 months following each transplantation. The clinical trial is intended to conclude within one year of the graft transplantations, see Immediate Report of April 29, 2014, Ref: 2014-01-052269.

Support offered by the Chief Scientist constitutes 40% of the approved budget, subject to payment of royalties from all income generated by Bonus Therapeutics Ltd. and submission of complementary documents.

The Company strives to enhance its technological expertise by rigorous R&D activities and through collaborations with other entities aimed at purchasing and/or obtaining exclusive rights to relevant technologies.

Bonus BioGroup's assessments regarding the set-up of the clinical trial, the number of participants, dates of clinical trial stages, trial completion and proof of safety and efficacy include forward-looking statements based on information available at the time of this report, as defined in the Securities Law – 1968. Whether actual results will conform, partially or fully, with the Company's predictions is subject to various factors, including feasibility tests and/or delays in the clinical trial and/or difficulty in recruiting participating subjects and/or an arising need to carry out additional trials and/or unsuccessful stage/s in the trial and/or technological changes and/or development and marketing of competitive/ore efficient product/s and/or materialization of any of the risk factors associated with the clinical trial and/or its outcomes.  

Read 1428 times Last modified on Tuesday, 11 December 2018 08:50


Press Release, Announcements publication and more

Bonus BioGroup



Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.